Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03913338
Other study ID # 154/14
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 24, 2014
Est. completion date July 3, 2018

Study information

Verified date April 2019
Source University Clinic Frankfurt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are to evaluate the safety and efficacy of a treatment regimen for high myopia and myopic astigmatism: LASIK followed by crosslinking performed with the KXL Crosslinking-System and VibeX Xtra (Riboflavin Ophthalmic Solution, Avedro, USA), as compared to LASIK alone, with regards to regression of refractive outcome, as measured by manifest refraction spherical equivalent (MRSE) and keratometry.


Description:

This is a controlled study of the safety and efficacy of the KXL System and VibeX Xtra (Riboflavin Ophthalmic Solution, Avedro, USA) for performing crosslinking in eyes undergoing LASIK for high myopia or myopic astigmatism. Each subject will have bilateral LASIK performed and one eye will be randomized to undergo LASIK followed by crosslinking.

Subjects will undergo bilateral LASIK. Following randomisation one eye of each subject will be treated with VibeX Xtra (Riboflavin Ophthalmic Solution) following LASIK and will be irradiated with the KXL System at 30 mW/cm2 intensity for 90 seconds continuous UV-A light treatment for a total radiant exposure of 2.7 J /cm2.

All eyes will be assessed at 1 day, 1, 3, 6, and 12 months after treatment.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date July 3, 2018
Est. primary completion date July 3, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- eligible for bilateral myopic fs-LASIK with -6.00 to -12.00 D (diopters) with a maximum of 5.00 D astigmatism

- age > 18 years

- provided written informed consent

- difference between the MRSE and cycloplegic SE less than 0.75 D

- MRSE needed to be stable for the last 12 months (<0.5 D).

Exclusion Criteria:

- prior corneal surgery,

- forme fruste or manifest keratoconus,

- history of corneal scarring, melting, ulceration

- repeating inflammations of the eye

- taking vitamin C 1 week prior to the treatment

Study Design


Intervention

Procedure:
LasikXtra
By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
LASIK
Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.

Locations

Country Name City State
Germany Department of ophthalmology University clinic Frankfurt Frankfurt am Main Hessen

Sponsors (2)

Lead Sponsor Collaborator
University Clinic Frankfurt Avedro, Inc.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary uncorrected distant visual acuity uncorrected distant visual acuity (logarithmic minimum angle of resolution) 12 months postoperative
Primary best spectacle corrected distant visual acuity best spectacle corrected distant visual acuity (logarithmic minimum angle of resolution) 12 months postoperative
Primary spherical equivalent spherical equivalent (diopter) 12 months postoperative
Secondary endothelial cell count endothelial cell count (number of cells/ mm2) 12 months postoperative
Secondary Corneal thickness Corneal thickness (micro millimeter) 12 months postoperative
Secondary Subjective visual quality Questionnaire regarding subjective optical quality (scale from 0 - 100; 0 = minimal, 100 = maximum) 12 months postoperative
See also
  Status Clinical Trial Phase
Recruiting NCT04923841 - Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine N/A
Active, not recruiting NCT04080128 - Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control N/A
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Completed NCT04604405 - Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation N/A
Recruiting NCT05594719 - The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow N/A
Completed NCT05594732 - The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow N/A
Completed NCT04492397 - Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI) N/A
Completed NCT04536571 - Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses N/A
Completed NCT06046209 - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens N/A
Recruiting NCT06344572 - Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia Phase 3
Recruiting NCT05611294 - Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction N/A
Completed NCT05656885 - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses N/A
Active, not recruiting NCT05534022 - Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression. N/A
Completed NCT03934788 - the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens N/A
Completed NCT03701516 - Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2 N/A
Completed NCT05538754 - Post-Market Evaluation of the EVO ICL N/A
Completed NCT03139201 - Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens N/A
Completed NCT02555722 - Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear N/A
Not yet recruiting NCT06009458 - Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear N/A
Recruiting NCT05548478 - Corneal Endothelial Cell Injury Induced by Mitomycin-C N/A